Novartis presents new drug data at American Headache Society annual meeting

Novartis has announced that it will be presenting its latest migraine research findings at this week's annual scientific meeting of the American Headache Society.

The company is attending the event in Boston, which runs from June 8th to 11th, to present 19 scientific abstracts, including a new analysis from a study highlighting the efficacy of erenumab – also known as AMG 334 – in patients with 15 or more headache days a month.

Erenumab is the first fully human monoclonal antibody therapy specifically designed to target and block the calcitonin gene-related peptide receptor, which is believed to play a critical role in mediating the incapacitating pain caused by migraines.

Additional data from the phase III STRIVE and ARISE studies – which involved people who experience four to 14 migraine days per month – will also be shared, in addition to a presentation on the recent history of acute migraine medication overuse.

Vasant Narasimhan, global head of drug development and chief medical officer for Novartis, said: "We are confident that with erenumab, we are a step closer to offering a preventive therapy that is both efficacious and well-tolerated, ultimately helping patients to claim their lives back."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.